These adverse reactions were usually transient and did not generally lead to cessation of therapy.
Tabulated list of adverse reactions: The table as follows gives the adverse reactions observed from clinical trials and post marketing spontaneous reports.
Adverse reactions are listed as follows using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data). The frequencies have not been corrected for placebo. (See table.)

View ADR Reporting Link